HR 916
103th Congress
House
Health
Advice and consent of the Senate
Congressional reporting requirements
Cost of living adjustments
Department of Health and Human Services
Drug industry
Drugs
Excess profits tax
Executive reorganization
Income tax
Patents
Prescription pricing
Presidential appointments
Price regulation
Restrictive trade practices
Tax preferences
Taxation
Prescription Drug Prices Review Board Act of 1993
Introduced: February 16, 1993
See on congress.gov
Everywhere this bill has been
19 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 27, 1993
Sponsor introductory remarks on measure. (CR E1889)
Jul 14, 1993
Referred to the Subcommittee on Intellectual Property and Judicial Administration.
Jul 13, 1993
Sponsor introductory remarks on measure. (CR E1745-1746)
Jun 23, 1993
Sponsor introductory remarks on measure. (CR E1598)
Jun 17, 1993
Sponsor introductory remarks on measure. (CR E1539)
Jun 16, 1993
Sponsor introductory remarks on measure. (CR E1532-1533)
Jun 14, 1993
Sponsor introductory remarks on measure. (CR E1486)
Jun 8, 1993
Sponsor introductory remarks on measure. (CR E1419-1420)
May 25, 1993
Sponsor introductory remarks on measure. (CR E1346)
May 18, 1993
Sponsor introductory remarks on measure. (CR E1273)
May 13, 1993
Sponsor introductory remarks on measure. (CR H2486)
May 5, 1993
Sponsor introductory remarks on measure. (CR E1152-1153)
Mar 24, 1993
Sponsor introductory remarks on measure. (CR E760)
Mar 1, 1993
Referred to the Subcommittee on Health and the Environment.
Feb 17, 1993
Sponsor introductory remarks on measure. (CR H658-659)
Feb 16, 1993
Referred to the House Committee on Ways and Means.
Feb 16, 1993
Referred to the House Committee on Judiciary.
Feb 16, 1993
Referred to the House Committee on Energy and Commerce.
Feb 16, 1993
Introduced in House
Plain-English summary
Prescription Drug Prices Review Board Act of 1993 - Establishes in the Food and Drug Administration the Patented Medicine Prices Review Board which shall have the power to decrease the length of term of a prescription drug patent if, after notice and a hearing, it is found that the drug's price is excessive. Defines the term excessive price. Allows the Board to require the recapture of tax benefits provided to the patentee of an excessively priced drug.
What's happening now
Sponsor introductory remarks on measure. (CR E1889)